Exposure to secondhand aerosol of electronic cigarettes in indoor settings in 12 European countries: data from the TackSHS survey


Por: Amalia, B, Liu, XQ, Lugo, A, Fu, M, Odone, A, van den Brandt, PA, Semple, S, Clancy, L, Soriano, JB, Fernandez, E, Gallus, S, Lopez, MJ, Continente X., TackSHS Project Investigators

Publicada: 1 ene 2021
Resumen:
Introduction Exposure to secondhand aerosol from e-cigarette (SHA) may pose harmful effects to bystanders. This study aims to investigate the prevalence, duration and determinants of SHA exposure in various indoor settings in 12 European countries. Methods In 2017-2018, we conducted a cross-sectional study, the TackSHS survey, on a representative sample of the population aged >= 15 years in 12 European countries (Bulgaria, England, France, Germany, Greece, Ireland, Italy, Latvia, Poland, Portugal, Romania and Spain). We described the prevalence and duration of exposure to SHA in several indoor settings among 11 604 e-cigarette non-users. Individual-level and country-level characteristics associated with SHA exposure were also explored using multilevel logistic regression analyses. Results Overall, 16.0% of e-cigarette non-users were exposed to SHA in any indoor setting at least weekly, ranging from 4.3% in Spain to 29.6% in England. The median duration of SHA exposure among those who were exposed was 43 min/day. 'Other indoor settings' (eg, bar and restaurant) was reported as the place where most of e-cigarette non-users were exposed (8.3%), followed by workplace/educational venues (6.4%), home (5.8%), public transportation (3.5%) and private transportation (2.7%). SHA exposure was more likely to occur in certain groups of non-users: men, younger age groups, those with higher level of education, e-cigarette past users, current smokers, those perceiving SHA harmless and living in countries with a higher e-cigarette use prevalence. Conclusions We found inequalities of SHA exposure across and within European countries. Governments should consider extending their tobacco smoke-free legislation to e-cigarettes to protect bystanders, particularly vulnerable populations such as young people.

Filiaciones:
Amalia, B:
 Catalan Inst Oncol ICO, Tobacco Control Unit, Lhospitalet De Llobregat 08908, Catalonia, Spain

 Catalan Inst Oncol ICO, WHO Collaborating Ctr Tobacco Control, Lhospitalet De Llobregat, Catalonia, Spain

 Bellvitge Inst Biomed Res IDIBELL, Tobacco Control Res Grp, Lhospitalet De Llobregat, Catalonia, Spain

 Univ Barcelona UB, Dept Clin Sci, Lhospitalet De Llobregat, Catalonia, Spain

 CIBER Resp Dis CIBERES, Madrid, Spain

Liu, XQ:
 IRCCS Ist Ric Farmacol Mario Negri, Dept Environm Hlth Sci, Milan, Italy

Lugo, A:
 IRCCS Ist Ric Farmacol Mario Negri, Dept Environm Hlth Sci, Milan, Italy

Fu, M:
 Catalan Inst Oncol ICO, Tobacco Control Unit, Lhospitalet De Llobregat 08908, Catalonia, Spain

 Catalan Inst Oncol ICO, WHO Collaborating Ctr Tobacco Control, Lhospitalet De Llobregat, Catalonia, Spain

 Bellvitge Inst Biomed Res IDIBELL, Tobacco Control Res Grp, Lhospitalet De Llobregat, Catalonia, Spain

 Univ Barcelona UB, Dept Clin Sci, Lhospitalet De Llobregat, Catalonia, Spain

 CIBER Resp Dis CIBERES, Madrid, Spain

Odone, A:
 Univ Vita Salute San Raffaele, Sch Publ Hlth, Milan, Lombardia, Italy

van den Brandt, PA:
 Maastricht Univ Med Ctr, CAPHRI Sch Publ Hlth & Primary Care, Maastricht, Netherlands

Semple, S:
 Univ Stirling, Inst Social Mkt, Stirling, Scotland

Clancy, L:
 TobaccoFree Res Inst Ireland TFRI, Dublin, Ireland

Soriano, JB:
 CIBER Resp Dis CIBERES, Madrid, Spain

 Hosp Univ Princesa, Resp Dept, Madrid, Spain

Fernandez, E:
 Catalan Inst Oncol ICO, Tobacco Control Unit, Lhospitalet De Llobregat 08908, Catalonia, Spain

 Catalan Inst Oncol ICO, WHO Collaborating Ctr Tobacco Control, Lhospitalet De Llobregat, Catalonia, Spain

 Bellvitge Inst Biomed Res IDIBELL, Tobacco Control Res Grp, Lhospitalet De Llobregat, Catalonia, Spain

 Univ Barcelona UB, Dept Clin Sci, Lhospitalet De Llobregat, Catalonia, Spain

 CIBER Resp Dis CIBERES, Madrid, Spain

Gallus, S:
 IRCCS Ist Ric Farmacol Mario Negri, Dept Environm Hlth Sci, Milan, Italy

Lopez, MJ:
 Institut d’Investigació Biomèdica Sant Pau (IIB SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain

Continente X.:
 Institut d’Investigació Biomèdica Sant Pau (IIB SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain
ISSN: 09644563
Editorial
BMJ PUBLISHING GROUP, BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 30 Número: 1
Páginas: 49-56
WOS Id: 000608389100009
ID de PubMed: 32123139
imagen Green Accepted

MÉTRICAS